Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07647432 Elranatamab Plasmablastic Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07647432 clinical trial report covering Elranatamab, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07651163 Lisaftoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07651163 clinical trial report covering Lisaftoclax, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07651176 Lisaftoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07651176 clinical trial report covering Lisaftoclax, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07660536 Doxercalciferol Osteoporosis, Postmenopausal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07660536 clinical trial report covering Doxercalciferol, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07669402 Letrozole Oligospermia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07669402 clinical trial report covering Letrozole, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07648914 Izalontamab Brengitecan HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07648914 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07648264 Normal Human Immunoglobulin (CSL Behring) Secondary immunodeficiencies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07648264 clinical trial report covering Normal Human Immunoglobulin (CSL Behring), Phase 3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07648225 UBT-251 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07648225 clinical trial report covering UBT-251, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07650942 Mufemilast Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07650942 clinical trial report covering Mufemilast, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07650227 Rifampin Acute Bronchitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07650227 clinical trial report covering Rifampin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07650916 Cabotegravir sodium HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07650916 clinical trial report covering Cabotegravir sodium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07649122 68Ga-NYM032 Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07649122 clinical trial report covering 68Ga-NYM032, Phase 3, endpoints, sponsor, geography, readout timing and development white space.